4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.
加州埃默里维尔，2024年8月12日（环球新闻社） - 4D分子治疗（纳斯达克：FDMt，4DMt或公司），一家领先的临床遗传药物公司，致力于释放遗传药物治疗大型市场疾病的全部潜力，今天宣布管理层将参加 H.C. Wainwright 第4届年度眼科虚拟会议的座谈会。管理团队成员也将为一对一会议提供服务。
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
H.C. Wainwright第四届年度在线眼科医疗大会
| Presentation Date: | Thursday, August 15, 2024 |
| Presentation Time: | 12:00 p.m. ET |
| Webcast Link: | Webcast |
| 演示日期： | 2024年8月15日，星期四 |
| 演示时间： | 美国东部时间下午12:00 |
| 网络链接： | 网络转播 |
An archived copy of the webcast will be available for up to one year by visiting the "Investors" section of the 4DMT website at .
可通过访问4DMt网站的“投资者”部分，在一年之内检索网络研讨会的存档副本。
About 4DMT
关于4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT's proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.
4DMt是一家领先的临床遗传药物公司，专注于释放眼科和肺病领域遗传药物治疗大型市场疾病的全部潜力。4DMT的专有发明平台 Therapeutic Vector Evolution 将诺贝尔奖获奖技术定向进化的力量与近十亿个合成 AAV 壳体派生序列相结合，以发明用于我们的全资和合作产品候选人的定制和演变载体。我们的产品设计、开发和制造引擎帮助我们高效地创建和推进我们多样化的产品管道，旨在以潜在的治愈疗法革新医学，服务于数百万患者。目前，4DMt正在推进六个临床阶段和一个临床前产品候选人，每个产品都旨在治疗眼科、肺病和心脏病等罕见和大型市场疾病。此外，4DMt 也通过基因编辑合作推进了中枢神经系统计划。4D分子治疗、4DMt、治疗载体进化和 4DMt 徽标均为 4DMt 的商标。
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
我们所有的产品候选者都处于临床或临床前阶段，并尚未获得美国食品和药物管理局（FDA）或任何其他监管机构的营销批准。对于它们正在研究的治疗用途的安全性或有效性，不发表任何声明。
Learn more at and follow us on LinkedIn.
了解更多信息，请访问并在LinkedIn上关注我们。
Contacts:
联系人：
Media:
媒体：
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
凯瑟琳·史密斯
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
投资者：
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
朱利安·裴
投资者关系和企业财务负责人
Investor.Relations@4DMT.com